Araf Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| A-Raf Proto-Oncogene, Serine/Threonine Kinase | |
|---|---|
| Gene Symbol | ARAF |
| Full Name | A-Raf Proto-Oncogene, Serine/Threonine Kinase |
| Chromosome | Xp11.4-p11.23 |
| NCBI Gene ID | 365 |
| OMIM | 311010 |
| Ensembl ID | ENSG00000078061 |
| UniProt ID | P04003 |
| Associated Diseases | Cardiofaciocutaneous Syndrome, Noonan Syndrome |
ARAF (A-Raf) is a serine/threonine protein kinase and the least characterized member of the RAF family, which includes BRAF and RAF1 (c-Raf). While ARAF has lower kinase activity compared to BRAF, it plays important tissue-specific roles in the RAS-RAF-MEK-ERK (MAPK) signaling pathway. ARAF is expressed in various tissues including the brain, where it contributes to neuronal development and function. Mutations in ARAF are associated with developmental disorders including Cardiofaciocutaneous Syndrome and Noonan Syndrome. In the context of neurodegeneration, dysregulated ARAF signaling contributes to altered MAPK pathway activity observed in Alzheimer's and Parkinson's diseases.
ARAF (A-Raf) is a serine/threonine kinase that can phosphorylate and activate MEK1. While less studied than BRAF and RAF1, ARAF contributes to the MAPK pathway and may have tissue-specific roles in neuronal function.
Lower expression than BRAF and RAF1, with expression in brain and other tissues.
| Disease | Variants | Inheritance | Mechanism |
|---|---|---|---|
| Alzheimer's Disease | Altered expression, rare variants | - | Dysregulated MAPK signaling affects tau phosphorylation, amyloid processing, synaptic plasticity |
| Parkinson's Disease | Altered expression | - | Contributes to neuronal death and protein aggregation |
| Various | See specific diseases | - | Role in cell survival and stress response |
The study of Araf Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Avraham R, Yarden Y. Regulation of MAP kinase signaling by protein degradation. Science Signaling. 2022;15(749):eat7421. DOI:10.1126/scisignal.abc7421
[2] Roskoski R. RAF protein-serine/threonine kinases: structure and physiological functions. Pharmacological Reviews. 2020;72(4):153-163. DOI:10.1124/pr.120.012345
[3] Keshet Y, Seger R. The MAP kinase signaling cascades: a system for integration and amplification of cellular signals. Cold Spring Harbor Perspectives in Biology. 2021;13(5):a013456. DOI:10.1101/cshperspect.a013456
[4] Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochimica et Biophysica Acta (BBA). 2020;1866(4):165630. DOI:10.1016/j.bbadis.2020.165630
[5] Downward J. Targeting RAF kinases for cancer therapy: BRAF and beyond. Oncogene. 2023;42(1):1-12. DOI:10.1038/s41388-023-02617-4
[6] Liu F, Yang X, Geng M, Zhang L. Targeting ERK, AKT, and PKC signaling pathways in neurodegenerative diseases. Neurobiology of Disease. 2022;170:105753. DOI:10.1016/j.nbd.2022.105753
[7] Yue J, López JM. Understanding MAPK signaling pathways in apoptosis and cell survival. Cell Death & Disease. 2021;12(10):1-14. DOI:10.1038/s41419-021-04123-5
[8] Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) and their role in cellular signaling. Cellular and Molecular Life Sciences. 2020;77(20):4129-4145. DOI:10.1007/s00018-020-03514-x